Stefan Knapp

Stefan Knapp

SGC Frankfurt

Knapp

Biography

Prof Stefan Knapp studied Chemistry at the University of Marburg (Germany) and at the University of Illinois (USA). He did his PhD in protein crystallography at the Karolinska Institute in Stockholm (Sweden) (1996) and continued his career at the Karolinska Institute as a postdoctoral scientist (1996-1999). In 1999, he joined the Pharmacia Corporation as a principal research scientist in structural biology and biophysics. He left the company in 2004 to set up a research group at the Structural Genomics Consortium at Oxford University (SGC). From 2008 to 2015 he was a Professor of Structural Biology at the Nuffield Department of Clinical Medicine (NDM) at Oxford University (UK) and between 2012 and 2015 he was the Director for Chemical Biology at the Target Discovery Institute (TDI). He joined Frankfurt University (Germany) in 2015 as a Professor of Pharmaceutical Chemistry and the Buchmann Institute of Molecular Life Sciences. He remains associated to the SGC as a visiting Professor at Oxford and he is also adjunct Professor of the George Washington University. Since 2017 he is the CSO of the newly founded SGC node at the Goethe-University Frankfurt. His research interests are the rational design of selective inhibitors that target protein kinases as well as protein interactions modules that function as reader domains of the epigenetic code.

Research Areas

My laboratory is interested in understanding molecular mechanisms that regulate protein function of key signalling molecules and how these mechanisms can be utilized for the development of highly selective and potent inhibitors (chemical probes). As a basis for this work we have generated a comprehensive set of high resolution crystal structures that cover most members of the protein family of interest. We are particularly interested in protein interactions module of the bromodomain family that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks. This effort generated several highly selective chemical probes targeting bromodomains. A second research focus is on protein kinases. Our laboratory has solved a comprehensive set of crystal structure of this large protein family offering the opportunity to understand molecular mechanisms of their regulation and developing new strategies for their selective targeting. We developed for example a number of highly selective inhibitors by exploring unusual binding modes and allosteric binding sites. A particular focus of the laboratory is also to understand structural mechanisms leading to slow binding kinetics as part of the K4DD consortium.

2017

Hyperactive locomotion in a Drosophila model is a functional readout for the synaptic abnormalities underlying fragile X syndrome.

Kashima R, Redmond PL, Ghatpande P, Roy S, Kornberg TB, Hanke T, Knapp S, Lagna G, Hata A

Sci Signal. 2017-5-2 . 10(477): .doi: 10.1126/scisignal.aai8133

PMID: 28465421

Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.

Bataille CJ, Brennan MB, Byrne S, Davies SG, Durbin M, Fedorov O, Huber KV, Jones AM, Knapp S, Liu G, Nadali A, Quevedo CE, Russell AJ, Walker RG, Westwood R, Wynne GM

Bioorg. Med. Chem.. 2017-2-28 . .doi: 10.1016/j.bmc.2017.02.056

PMID: 28341403

Development of potent, selective SRPK1 inhibitors as potential topical therapeutics for neovascular eye disease.

Batson J, Toop HD, Redondo C, Babaei-Jadidi R, Chaikuad A, Wearmouth SF, Gibbons B, Allen C, Tallant C, Zhang J, Du C, Hancox J, Hawtrey T, Da Rocha J, Griffith R, Knapp S, Bates DO, Morris JC

ACS Chem. Biol.. 2017-1-30 . .doi: 10.1021/acschembio.6b01048

PMID: 28135068

Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies.

Igoe N, Bayle ED, Fedorov O, Tallant C, Savitsky P, Rogers C, Owen DR, Deb G, Somervaille TC, Andrews DM, Jones N, Cheasty A, Ryder H, Brennan PE, Müller S, Knapp S, Fish PV

J. Med. Chem.. 2017-1-9 . .doi: 10.1021/acs.jmedchem.6b01583

PMID: 28068087

2016

Predictions of ligand selectivity from absolute binding free energy calculations.

Aldeghi M, Heifetz A, Bodkin MJ, Knapp S, Biggin PC

J. Am. Chem. Soc.. 2016-12-23 . .doi: 10.1021/jacs.6b11467

PMID: 28009512

Identification of CLK1 Inhibitors by a Fragment-linking Based Virtual Screening.

Walter A, Chaikuad A, Loaëc N, Preu L, Knapp S, Meijer L, Kunick C, Koch O

Mol Inform. 2016-12-21 . .doi: 10.1002/minf.201600123

PMID: 28000414

BRD4 promotes p63 and GRHL3 expression downstream of FOXO in mammary epithelial cells.

Nagarajan S, Bedi U, Budida A, Hamdan FH, Mishra VK, Najafova Z, Xie W, Alawi M, Indenbirken D, Knapp S, Chiang CM, Grundhoff A, Kari V, Scheel CH, Wegwitz F, Johnsen SA

Nucleic Acids Res.. 2016-12-15 . .doi: 10.1093/nar/gkw1276

PMID: 27980063

Discovery of a PCAF Bromodomain Chemical Probe.

Moustakim M, Clark PG, Trulli L, Fuentes de Arriba AL, Ehebauer MT, Chaikuad A, Murphy EJ, Mendez-Johnson J, Daniels D, Hou CD, Lin YH, Walker JR, Hui R, Yang H, Dorrell L, Rogers CM, Monteiro OP, Fedorov O, Huber KV, Knapp S, Heer J, Dixon DJ, Brennan PE

Angew. Chem. Int. Ed. Engl.. 2016-12-14 . .doi: 10.1002/anie.201610816

PMID: 27966810

CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation.

Olzscha H, Fedorov O, Kessler BM, Knapp S, La Thangue NB

Cell Chem Biol. 2016-12-10 . .doi: 10.1016/j.chembiol.2016.11.009

PMID: 27989401

Discovery of New Bromodomain Scaffolds by Biosensor Fragment Screening.

Navratilova I, Aristotelous T, Picaud S, Chaikuad A, Knapp S, Filappakopoulos P, Hopkins AL

ACS Med Chem Lett. 2016-12-8 . 7(12):1213-1218 .doi: 10.1021/acsmedchemlett.6b00154

PMID: 27994766